This MedLibrary.org supplementary page on Cycloserine is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
This article or section includes a list of references or external links, but its sources remain unclear because it has insufficient in-text citations. You can improve this article by introducing more precise citations where appropriate. |
 |
|
|
Cycloserine
|
|
| Systematic (IUPAC) name | |
| 4-aminoisoxazolidin-3-one | |
| Identifiers | |
| CAS number | |
| ATC code | J04 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C3H6N2O2 |
| Mol. mass | 102.092 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ~70% to 90% |
| Metabolism | Hepatic |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
C |
| Legal status | |
| Routes | Oral |
Cycloserine is an antibiotic effective against Mycobacterium tuberculosis. For the treatment of tuberculosis, it is classified as a second line drug, i.e. its use is only considered if one or more first line drugs cannot be used.
Although in principle active against other bacteria as well, cycloserine is not commonly used in the treatment of infections other than tuberculosis.
Mode of action
The terminal two amino acid residues of the murein precursor lipid II consist of D-alanine, which is produced by the enzyme alanine racemase; the two residues are joined by D-alanine ligase. Both enzymes are competitively inhibited by cycloserine
Applications and side effects unrelated to antibiotic activity
It is also being trialed for treatment of phobias[1] as well as an adjuvant to conventional treatments for depression, obsessive-compulsive disorder and schizophrenia. It has been experimentally used for treatment of Gaucher's disease.
Recent research suggests that D-cycloserine may be effective in treating chronic pain.[2]
The side effects are mainly central nervous system (CNS) manifestations, i.e. headache, irritability, depression, convulsions. Co-administration of pyridoxine can reduce the incidence of some of the CNS side effects (e.g. convulsions).
These psychotropic responses are related to D-cycloserine's action as a partial agonist of the neuronal NMDA receptor for glutamate and have been examined in implications with sensory-related fear extinction in the amygdala.[1]
References
- ^ a b Davis, Michael; Karyn M. Myers, Kerry J. Ressler and Barbara O. Rothbaum (2005). "Facilitation of Extinction of Conditioned Fear by D-Cycloserine". American Psychological Society 14 (4): 214–219. doi:. Retrieved on 2008-07-15.
- ^ "Newly Identified Drug Relieves Suffering", Science Daily (2007-06-05). Retrieved on 2008-07-15.
|
||||||||||||||||||||||
Wikipedia content modification information:
- This page was last modified on 23 August 2008, at 07:18.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Cycloserine".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.